Genetic and proteomic approaches to identify cancer drug targets

por Roti, G, Stegmaier, K
Publicado 2012

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

por Lindblad, O, Cordero, E, Puissant, A, Macaulay, L, Ramos, A, Kabir, N N, Sun, J, Vallon-Christersson, J, Haraldsson, K, Hemann, M T, Borg, Å, Levander, F, Stegmaier, K, Pietras, K, Rönnstrand, L, Kazi, J U
Publicado 2016